Citi raised the firm’s price target on Fresenius Medical (FMS) to EUR 52.50 from EUR 46.50 and keeps a Neutral rating on the shares.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FMS:
- Fresenius Medical Care Expands U.S. Rollout of 5008X CAREsystem
- Fresenius Medical Care Announces Record Dividend and Strategic Milestones at AGM
- Fresenius Medical price target raised to EUR 43 from EUR 41 at Morgan Stanley
- Fresenius Medical Care Faces FTC Probe and Sells Latin American Clinics Amidst Labor Strikes
- Fresenius Medical price target raised to $30 from $25 at Truist